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Background: Rio de Janeiro and Niterói are neighbouring cities in 
southeastern Brazil which experience large dengue epidemics every 2 
to 5 years, with >100,000 cases notified in epidemic years. Costs of 
vector control and direct and indirect costs due to the Aedes-borne 
diseases dengue, chikungunya and Zika were estimated to total $650 
million USD in 2016, but traditional vector control strategies have not 
been effective in preventing mosquito-borne disease outbreaks. The 
Wolbachia method is a novel and self-sustaining approach for the 
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biological control of Aedes-borne diseases, in which the transmission 
potential of Aedes aegypti mosquitoes is reduced by stably transfecting 
them with the Wolbachia bacterium (wMel strain). This paper describes 
a study protocol for evaluating the effect of large-scale non-
randomised releases of Wolbachia-infected mosquitoes on the 
incidence of dengue, Zika and chikungunya in the two cities of Niterói 
and Rio de Janeiro. This follows a lead-in period since 2014 involving 
intensive community engagement, regulatory and public approval, 
entomological surveys, and small-scale pilot releases. 
Method: The Wolbachia releases during 2017-2019 covered a 
combined area of 170 km2 with a resident population of 1.2 million, 
across Niterói and Rio de Janeiro. Untreated areas with comparable 
historical dengue profiles and demographic characteristics have been 
identified a priori as comparative control areas in each city. The 
proposed pragmatic epidemiological approach combines a controlled 
interrupted time series analysis of routinely notified suspected and 
laboratory-confirmed dengue and chikungunya cases, together with 
monitoring of Aedes-borne disease activity utilising outbreak signals 
routinely used in public health disease surveillance. 
Discussion: If the current project is successful, this model for control 
of mosquito-borne disease through Wolbachia releases can be 
expanded nationally and regionally.
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Background
The global incidence of dengue has increased dramatically in 
recent decades. Although cases are underreported, it is estimated 
that 390 million dengue virus infections occur every year, and 
of these 96 million have clinical manifestations of dengue or 
severe dengue. Globally, 3.9 billion people in 128 countries are 
at risk of infection1. The primary vector of dengue is the 
Aedes aegypti mosquito, which is also capable of transmitting 
other arboviruses (i.e. mosquito-borne viruses) including 
chikungunya, Zika, yellow fever and Mayaro2.
The first reported dengue outbreak in Brazil was in 1845, with 
subsequent outbreaks in 1880–1912 and 1916–19232. As a 
result of a coordinated effort from the Pan American Health 
Organization (PAHO) and the World Health Organization (WHO) 
to eradicate Ae. aegypti, Brazil was considered free of the 
mosquito in 1955, but the vector was reintroduced into the 
country two decades later3. In 1986, dengue virus serotype 
1 (DENV1) was introduced to Rio de Janeiro and an estimated 
1 million people were infected3,4. Since then, dengue has become 
a major public health problem. From 1986 to 1993, outbreaks 
occurred approximately every 2–5 years, and from 1993 dengue 
became endemic with seasonal peaks in cases during the rainy 
season (December to May), but with ongoing transmission 
throughout the year2,3. Between 2000 and 2007, more than 
3 million dengue cases were reported (caused by DENV serotypes 
1, 2 and 3) and in 2010, DENV4 re-emerged after 28 years of 
absence2.
The recent introduction of Zika and chikungunya in dengue 
hyperendemic areas of Brazil has aggravated the situation. The 
overlapping clinical features, absence of serological assays for 
the Zika virus that can reliably distinguish between acute disease 
and past exposure, and the association of pregnancy-associated 
Zika virus infection with microcephaly and other neurologic 
complications represents a great challenge for public health that 
will require new strategies and innovations5,6.
Between 2016 and 2017, 762 deaths were attributed to severe 
dengue in Brazil7. Additionally, in 2017, 127 deaths were 
confirmed to be caused by chikungunya. Yellow fever has spread 
from the North of Brazil to the Southeast over the last years, 
affecting humans and non-human primates. From July 2017 
to April 2018, 1,266 cases of yellow fever including 415 deaths 
were confirmed in Brazil, with 223 cases and 73 deaths 
occurring  in Rio de Janeiro State8. No autochthonous cases 
were reported in Rio de Janeiro city or Niterói, although some 
residents from those cities acquired yellow fever while traveling 
to other places in Brazil. A mass vaccination campaign against 
yellow fever began in 2016.
The costs of vector control, direct medical costs, and indirect 
costs related to dengue, Zika and chikungunya in Brazil were 
estimated to be 2.3 billion Brazilian reais ($650 million USD) 
in 20169. In the absence of an effective vaccine for these 
arboviruses, disease prevention depends on vector control. Vector 
control guidelines in Brazil10 are focused on elimination or 
larvicide treatment of mosquito breeding sites and the control of 
adult mosquito populations with insecticides sprayed as ultra- 
low volume. The limited potential of these traditional vector 
control strategies to achieve large-scale and sustained reductions 
in dengue incidence is evidenced by the continuing public health 
burden of dengue throughout endemic areas where these measures 
are routinely employed, and the lack of robust efficacy data from 
well-designed trials to inform their optimal implementation11.
The Wolbachia method (www.worldmosquito.org) is a novel, 
natural, and self-sustaining approach to reduce arboviral diseases 
transmitted by Ae. aegypti mosquitoes. The symbiotic Wolbachia 
bacterium is found naturally in over 60% of insect species, but 
not in Ae. aegypti, and is passed from one generation to the next 
through the insect’s eggs. Stable transinfection of Wolbachia 
into a local Ae. aegypti colony in the laboratory produces a 
lineage of Wolbachia-carrying mosquitoes which, upon release 
over several weeks, can achieve dissemination of Wolbachia 
into the local Ae. aegypti population through the processes of 
maternal inheritance and cytoplasmic incompatibility that give 
Wolbachia-carrying mosquitoes a reproductive advantage. The 
DENV-transmitting potential of mosquitoes stably transfected with 
Wolbachia pipientis (wMel strain) is reduced by 66–75%12,13, a 
phenotype which has been shown to persist in field mosquito pop-
ulations up to five years after the end of releases. Mathematical 
modelling of this reduced transmissibility predicts a substantial 
and sustained reduction in dengue incidence in human populations 
where Wolbachia is established13. Laboratory data indicate a 
similar reduction in the competence of Wolbachia-carrying 
Ae. aegypti for transmitting other viruses including Zika, 
chikungunya, yellow fever and Mayaro14–17.
With releases now conducted in eight countries over the past 
eight years, the World Mosquito Program has demonstrated that 
Wolbachia can be successfully established and maintained in both 
small-scale and large-scale urban settings in multiple ecological 
environments18–22.
            Amendments from Version 1
The rationale for the non-randomised study design has been 
described in more detail. Language has been clarified throughout 
to refer to Aedes-borne disease instead of arboviral disease. The 
Niteroi intervention area has been updated to reflect additional 
releases within part of the original control area. Additional detail 
has been provided on the statistical methods for the ITS analysis. 
A graph of historical chikungunya incidence in the intervention 
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A core objective of these releases has been to ensure strong 
community acceptance and government support for the approach, 
achieved through embedding community and stakeholder 
engagement within the project activities in each site. Observational 
evidence of the impact of Wolbachia releases on arboviral 
disease in pilot sites has been encouraging, with no evidence of 
local dengue transmission where Wolbachia has established at 
high levels. Following city-wide deployment in Townsville, 
Australia, there has been no confirmed local dengue transmission 
in Wolbachia-treated areas for four seasons since completion 
of releases, despite local transmission every year for the prior 
13 years and ongoing importation of DENV infection in travelers21. 
A cluster randomized controlled trial (RCT) to generate a 
robust and quantitative estimate of the impact of Wolbachia on 
dengue incidence commenced in Yogyakarta, Indonesia in 2017, 
with reporting of results expected in 202123.
In Brazil, planned scale up of Wolbachia deployments from 
demonstration projects in Rio de Janeiro and Niterói to large-
scale releases was accelerated by the declaration of Zika as a 
public health emergency by the WHO in early 2016, and the 
recommendation by WHO’s Vector Control Advisory Group in 
March 2016 that the Wolbachia method be evaluated in rigorously 
monitored pilot deployments under operational conditions, to 
build evidence of epidemiological effectiveness against Aedes- 
borne viruses24. Given the imperative from stakeholders and 
funders to scale up deployment within a relative short time 
frame, and to retain sufficient flexibility to optimize methods for 
large-scale deployment in the varied micro-environments within 
Niterói and Rio de Janeiro, an RCT or other carefully controlled 
deployment was not considered feasible. Instead releases under 
operational conditions, and with pragmatic evaluation of disease 
impact using data routinely collected for public health purposes, 
was favoured. The primary reason that randomised deployment 
of the Wolbachia intervention was not undertaken (either by 
random allocation of treated and untreated areas, or by randomising 
the sequence of staged deployments) was the intensive 
community engagement effort required in release areas in 
advance of deployments, as well as the gains in logistical 
efficiency and entomological outcomes from staging deployments 
across large contiguous areas. The potential benefits of randomised 
allocation of deployments in reducing bias from known and 
unmeasured confounders would require the intervention (and 
control) areas to be divided into a large number of units for 
randomisation. This fragmentation of the deployment areas 
would have made the community engagement activities and 
deployment logistics infeasible. Having small, fragmented release 
areas interspersed with untreated areas would also have greatly 
increased the potential for contamination between treatment arms 
from both mosquito movement and human movement, thereby 
diluting the observable intervention effect.
Here we describe a protocol for evaluating the effect of large-
scale non-randomized Wolbachia releases on the incidence of 
dengue, chikungunya and Zika in the cities of Niterói and Rio 
de Janeiro. The proposed strategy employs a controlled inter-
rupted time series analysis of routinely notified suspected and 
laboratory-confirmed cases of dengue, chikungunya and Zika, 
together with monitoring of disease activity with outbreak signals 
routinely used in public health disease surveillance. This meth-
odology allows measurement of the impact of the intervention at 
the population level over time, accounting for the seasonal trends 




The aim of this epidemiological study is to test the hypothesis 
that the establishment of Wolbachia in local Ae. aegypti populations 
in Rio de Janeiro and Niterói leads to a reduction in the burden 
of Aedes-borne disease.
The impact of Wolbachia deployment on disease incidence 
will be evaluated using routine notifiable disease surveillance 
data to describe associations between temporal and spatial trends 
in dengue, chikungunya and Zika and the deployment of Wolbachia 
across Niterói and Rio de Janeiro, with two objectives:
1.    Estimate the reduction in dengue, chikungunya and Zika 
in the aggregate treated areas of Niterói and Rio de Janeiro 
compared to an untreated control area, and in each treated 
zone compared to the untreated control area, each year for 
five years after Wolbachia establishment.
2.    Quantify the occurrence of dengue outbreak signals in 
Wolbachia treated areas compared to untreated areas in 
Niterói and Rio de Janeiro, for five years after Wolbachia 
establishment, using outbreak indicators employed rou-
tinely for public health monitoring of dengue activity: 
i) control diagrams comparing the weekly dengue inci-
dence (five-week moving average) against the five-year 
historical average in that same area; and ii) outbreak 
incidence threshold of 300/100,000 population in any 
month.
Study setting and population
Rio de Janeiro and Niterói cities are located in the State of Rio 
de Janeiro, Brazil. Niterói has an area of 134 km2 and a population 
of 484,918 in 2010. Rio de Janeiro is the second largest city in 
Brazil with 6,320,446 inhabitants in 2010 and an area of 1,200 km2. 
The two cities sit on opposite sides of the Guanabara Bay and 
are linked by a long bridge, which transports a large commuter 
population between Niterói and Rio de Janeiro.
The cities are divided into health districts, for the purpose of 
planning and delivering care - ten in Rio de Janeiro and seven in 
Niterói. In Rio de Janeiro, Wolbachia deployments will be 
conducted in one of the administrative areas of the city (Figure 1; 
produced in ArcMap version 10.5, ESRI, CA), in an area of 
approximately 90 km2 and with 886,551 inhabitants, 39% of 
whom live in slums. The total release area in Niterói is approx-
imately 83 km2 covering a population of 373,117 (Table 1). For 
the purposes of Wolbachia deployment, the Rio de Janeiro and 
Niterói intervention areas are each divided into 4 release zones, 
respectively, which are aligned with neighbourhood administrative 
boundaries.
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Release Zone 1 4 23,747 9.2 2,581
Release Zone 2 11 68,695 50.6 1,357
Release Zone 3 13 178,891 12.6 14,197
Release Zone 4 5 101,784 10.8 9,424
Non-release control area 19 111,801 51.2 2,183
Total 52 484,918 134.4 3,608
Rio de Janeiro
Release Zone 1 10 107,130 11.8 9,078
Release Zone 2 6 150,646 33.5 4,496
Release Zone 3.1 8 408,036 28.2 14,469
Release Zone 3.2 4 220,739 12.0 18,394
Non-release control area 51 1,512,608 117.3 12,895
Rest of city (no releases) 79 3,921,287 996.5 3,935
Total 158 6,320,446 1,199.3 5,270
Figure 1. Map of (a) Rio de Janeiro and (b) Niterói Wolbachia-treated and untreated areas (produced in ArcMap version 10.5, ESRI, CA).
In Rio de Janeiro, two administrative areas adjacent to the 
release area have been designated a priori as a comparative con-
trol zone (Figure 1), based on synchronous historical dengue and 
chikungunya time series (Figure 2 and Figure 3). In Niterói, 
the remaining untreated area of the city has been designated as 
the comparative control zone (Figure 1).
Wolbachia release and monitoring
Staged wMel Wolbachia-mosquito deployments will be imple-
mented in Niterói and Rio de Janeiro, in order to achieve Wolbachia 
establishment across the two cities. Pilot releases commenced 
in late 2015, and city-wide deployments are ongoing through to 
the end of 2019. Wolbachia-containing adult mosquitoes will 
be released at one location per 50 x 50 meter grid square for 
a minimum of 16 consecutive weeks in each release zone. In 
areas where Wolbachia frequency remains low after 16 weeks of 
releases, or where particularly high wild type Ae. aegypti 
populations are observed, Wolbachia-containing mosquito eggs 
will also be released to complement adult releases with the aim 
of accelerating Wolbachia establishment. Monitoring of Wolbachia 
frequency will be done using BG-Sentinel mosquito traps 
(BioGents, Germany), distributed throughout the release area at 
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Figure 2. Dengue incidence in Wolbachia-treated vs untreated areas of (a) Rio de Janeiro (2000–2017) and (b) Niterói (2007–2017) (source: 
Brazilian National Disease Surveillance System (SINAN)).
Figure 3. Chikungunya incidence in Wolbachia-treated vs untreated areas of (a) Rio de Janeiro (2015–2017) and (b) Niterói (2015–2017) 
(source: Brazilian National Disease Surveillance System (SINAN)).
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a density of 16 traps per km2. Traps will be serviced weekly and 
all collected mosquitoes identified morphologically by microscopy. 
From eight weeks after the start of releases, a maximum of 
10 Ae. aegypti (male and female) per trap will be tested individu-
ally for Wolbachia using quantitative polymerase chain reac-
tion (qPCR). Wolbachia screening will be performed biweekly 
during releases and until establishment, then every 1–3 months 
thereafter. All surplus Ae. aegypti will be biobanked. Mosquito 
collection and screening results will be stored in a custom 
designed web-based data repository. The Wolbachia prevalence in 
screened Ae. aegypti will be reported aggregated to each release 
zone, calculated as the total number of Ae. aegypti mosqui-
toes that tested positive for Wolbachia aggregated across all BG 
traps in the zone, divided by the total number of Ae. aegypti 
that were screened in that zone.
Epidemiological data sources
The two proposed strategies for the evaluation of the impact of 
large-scale Wolbachia deployments on arboviral disease incidence 
in Niterói and Rio de Janeiro make use of existing data on dengue, 
chikungunya and Zika case notifications to the Brazilian national 
disease surveillance system (SINAN). Dengue surveillance has 
been in place since its re-emergence in 1986 and data is available 
from the SINAN system since 2000. Zika and chikungunya 
became notifiable diseases in 2015.
Suspected cases of dengue and other arboviral diseases are 
required to be reported to the city health department25, according 
to a case definition of fever plus two other symptoms including 
malaise, headache, myalgia, nausea, vomiting, cutaneous rash, 
and arthralgia. Dengue case notifications include an indication of 
disease severity (dengue, dengue with alarm signals, severe 
dengue, fatal dengue). A variable proportion of notified suspected 
cases are tested by IgM serology or PCR, following the Brazilian 
guidelines26 and the timing between onset of symptoms and 
blood collection. The number of cases in a given period of time 
may limit the availability of tests, and PCR testing is routinely 
performed only for severe and fatal cases, pregnant women and 
young children26. In 2016, 4.8% of notified dengue cases in Rio 
de Janeiro and 11.5% in Niterói were supported by a positive 
IgM serology result, and only 0.2% of notified cases in Rio 
and 0.03% in Niterói had a positive PCR result. The ability to 
confirm dengue cases by serology is impaired since the Zika 
outbreak due to serological cross-reactivity between the den-
gue and Zika viruses. As PCR testing is performed only in cer-
tain patient populations, the proportion positive is unlikely to be 
generalisable to all notified cases. Therefore, for the purpose 
of our analyses we will use all notified dengue cases (suspected 
and laboratory-confirmed) as the primary endpoint.
In the absence of a reliable serological test that does not 
cross-react with dengue, Zika lab diagnosis is done solely on 
the basis of molecular detection (real-time PCR) up to the first 
5 days in serum and 15 days in urine. This has severely limited 
the ability to confirm Zika virus infection among notified cases 
(3.5% in 2016, 19.3% in 2017).
Chikungunya diagnoses can be confirmed either through PCR 
or serology, as it does not cross-react with Zika or dengue. The 
proportion of notified cases with supportive laboratory findings 
is higher than for dengue: 31.9% and 18.2% in Rio and Niterói, 
respectively, in 2016.
Anonymized disaggregate (line-listed) data on notified suspected 
and laboratory-confirmed dengue, chikungunya and Zika cases 
will be extracted from the SINAN system for the historical 
pre-intervention period (2000–2016 for dengue, and 2015–2016 
for chikungunya and Zika) and the prospective post-intervention 
period (2017–2023). The dataset will include age, sex, neigh-
bourhood of primary residence, date of illness onset, date of 
notification, reporting health clinic, disease severity, hospitali-
sation, death, and where available, geocoordinates of primary 
residence, type of diagnostic test performed, diagnostic test 
result, and final diagnostic classification. Population data from the 
Brazilian census (IBGE) and population by neighbourhood of 
residence obtained from the cities of Rio and Niterói will be 
used to estimate the population in each release zone. The 
incidence rate (number of new dengue, Zika or chikungunya 
cases divided by the population at risk) will be expressed per 
100,000 inhabitants.
Controlled interrupted time series analysis
Interrupted time series (ITS) analysis is a valuable study design 
for evaluating the effectiveness of a population-level health inter-
vention that is implemented at a clearly defined point in time27. 
It uses a set of historical observations of an outcome of interest 
(in this context monthly dengue case notifications) to establish 
an underlying trend, which is assumed to be ‘interrupted’ by the 
introduction of an intervention (in this case Wolbachia releases). 
Comparison of the trend in monthly case notifications in the 
post-intervention period with the hypothetical scenario of no 
intervention (the ‘counterfactual’, inferred from the historical 
time series and the untreated control area), provides an estimate 
of the intervention effect. Segmented regression will be used to 
estimate the effect of Wolbachia releases on monthly case counts 
of dengue and chikungunya, using an appropriately defined model: 
e.g. negative binomial regression for autocorrelated count data 
with population offset, adjusted for temporal effects using 
indicator variables or flexible cubic splines, and assuming a step 
change post-intervention. The Wolbachia intervention effect 
will be estimated from the interaction between a binary ‘area’ 
variable (intervention vs control area) and a binary ‘period’ vari-
able (post-intervention vs pre-intervention). The post-intervention 
period will be defined for the control area beginning at the 
same time as the post-intervention period in the compara-
tive release zone. This allows explicitly for a level change in 
the outcome (dengue case incidence) in both intervention and 
control areas in the post-intervention period, for example in a 
scenario where other secular events coincident with the Wol-
bachia deployments may have influenced dengue incidence in 
both intervention and control areas independent of Wolbachia. 
An additional analysis will consider Wolbachia frequency as a 
continuous covariate or categorised into quintiles of exposure 
reflecting the measured Wolbachia prevalence in the local mos-
quito population. The outcome distribution is assumed to be nega-
tive binomial to allow for overdispersion. Robust standard errors 
will be used to account for autocorrelation and heteroskedasticity. 
If an excess of zero counts is apparent, the proposed negative 
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binomial model will be nested within a zero-inflated negative 
binomial model of the same structure. A likelihood ratio test can be 
performed to test model fit.
Separate analyses will be performed for each release zone 
compared with its pre-defined control area, and for the aggregate 
release areas in each city compared with the control area for each 
city. The availability of comparative control areas – well-matched 
to the release area in demographic characteristics and historical 
arboviral disease incidence (Figure 2 and Figure 3) – permits a 
robust, controlled analysis in which the confounding effects of 
seasonality and inter-annual variability can be adjusted for. The 
intervention effect will be estimated after 12 months of post-release 
observations have accumulated, and each 12 months thereafter 
for five years using cumulative post-release observations, for 
each release zone individually and in aggregate for each city.
Power was estimated for the ITS analysis using 1000 simulated 
datasets drawn from a negative binomial distribution fitted to a 
ten-year time series (2007–2016) prior to Wolbachia deployment, 
of monthly dengue case notifications from release and control 
zones in Niterói and Rio de Janeiro. The simulated time series 
of dengue case numbers in the control zones as well as the pre- 
Wolbachia release dengue case numbers in the treated zones 
were drawn directly from this model-generated distribution. Post- 
Wolbachia release dengue case numbers in the treated zones 
were drawn from the same model-generated distribution, modified 
by an additional parameter for an intervention effect of Relative 
Risks = 0.6, 0.5, 0.4, 0.3. For each of these four ‘true’ effect 
sizes and a null effect (RR = 1), applied to each of the 1000 
simulated time series, the ‘observed’ effect size was calculated 
from a negative binomial regression model of monthly case 
counts in the treated and untreated zones, as described above. 
Post-intervention time periods of 1, 2 or 3 years were simulated, 
with the pre-intervention period fixed at 7 years. The estimated 
power to detect a given effect size was determined as the 
proportion of the 1000 simulated scenarios in which a significant 
intervention effect (p<0.05) was observed. These simulations 
indicate 80% power to detect a reduction in dengue incidence of 
50% or greater after three years of post-intervention observations, 
and a reduction of 60% or greater after two years.
The primary endpoint for the ITS analysis will be dengue 
cases notified to the disease surveillance system. The secondary 
endpoints will be: a) the count of severe dengue cases reported 
to the surveillance system, b) the count of fatal dengue cases 
reported to the surveillance system, and c) chikungunya and 
Zika cases notified to the disease surveillance system.
Although the historical time series for chikungunya and Zika 
incidence is short, we will nonetheless describe the incidence 
during and after Wolbachia deployments relative to the a priori 
defined non-release control areas for both Niterói and Rio de 
Janeiro.
Dengue outbreak signals
As a complementary approach for evaluating the public health 
impact of large-scale Wolbachia releases, we will also use the 
following dengue outbreak alert tools routinely used in public 
health practice. We hypothesise that these dengue outbreak signals 
will not be triggered in areas where Wolbachia has been 
established.
1. Control diagram (endemic channel)
The definition of a dengue outbreak or epidemic has changed 
over time in Brazil. In Rio de Janeiro and Niterói, a control 
diagram is currently used to monitor dengue incidence. Briefly, 
the control diagram is constructed from a five-week centered 
moving average of weekly notified dengue incidence for the past 
five years excluding epidemic years. An early signal of a dengue 
outbreak/epidemic is triggered when the weekly incidence of 
dengue crosses the upper limit of the control diagram26, with the 
upper limit defined as [mean+(standard deviation*1.96)]. Inci-
dence that remains above the upper limit of the control diagram 
for two or more consecutive weeks constitutes a dengue outbreak. 
For the purpose of monitoring the impact of Wolbachia releases on 
dengue, we will construct annual control diagrams with 
weekly dengue incidence, by city and for each release and 
non-release zone, to monitor the occurrence of dengue outbreaks. 
The number of dengue outbreak signals triggered per year will 
be reported.
2. Classical incidence threshold
Another outbreak definition that has been used by the Ministry 
of Health (MoH) in previous years20,22,23 is a dengue incidence 
threshold of ≥300 cases/100,000 population in a given month. 
Although not included in current MoH guidelines, this provides an 
alternative endpoint for evaluating dengue activity at a population 
level in the post-intervention period, compared with pre- 
intervention, and we will report the number of months in a given 
year where dengue incidence crosses this threshold.
Current study status
This study is ongoing. Wolbachia releases are expected to be 
completed by the end of 2019, and the collation and analysis of 
disease surveillance data will continue until 2023.
Dissemination of study results
Based on the results of the power estimation above, the study 
outcome will be evaluated and reported two years after the 
completion of releases. The findings will be submitted for peer 
review and publication in an appropriate open access journal, 
together with aggregate supporting data.
Discussion
The two cities of Rio de Janeiro and Niterói in southeastern 
Brazil have been affected by dengue for more than 30 years, with 
epidemics occurring every 2 to 5 years. In recent years, outbreaks 
of the other Aedes-borne diseases chikungunya and Zika have 
presented further public health challenges. Vector control 
strategies, based on elimination of mosquito breeding sites and 
use of insecticides to reduce adult populations, have not been 
effective in preventing dengue outbreaks28. The Wolbachia 
method is a novel and self-sustaining approach for the biologi-
cal control of arboviral diseases. The signature feature of Wol-
bachia is to reduce the arbovirus-transmission potential of 
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Wolbachia-infected mosquitoes12,14,16,17. The World Mosquito 
Program29 is deploying wMel Wolbachia-infected Ae. aegypti 
mosquitoes in Brazil with the purpose of achieving a large-
scale and sustained reduction in arboviral disease burden in two 
cities where these diseases are public health priorities.
In March 2016, the WHO convened a Vector Control Advisory 
Group to review new and existing vector control tools for use in 
the response to the Zika virus outbreak. Based on the available evi-
dence that Wolbachia reduces the Zika, dengue and chikungunya 
transmission potential of Ae. aegypti mosquitoes and field data 
showing long-term establishment of Wolbachia in mosquito 
populations in a range of environmental settings, the WHO 
recommended carefully monitored pilot implementation of the 
Wolbachia method in affected countries24.
While RCTs are still considered the gold standard, they are  not 
always feasible or agreeable to the community and government. 
The controlled ITS analysis is a quasi-experimental design that 
is commonly used to evaluate population-level public health 
intervention27,30,31 and is a pragmatic alternative design where an 
RCT is considered infeasible, particularly in the presence of a 
well-matched untreated control area32,33. While the ITS approach 
could also be combined with randomization of the intervention, 
given the public health emergency posed by the Zika epidemic 
at the time of this study’s inception and the need to scale up 
Wolbachia deployment in Rio de Janeiro and Niterói within a 
relative short time frame, randomized allocation of the Wolbachia 
deployments was not considered feasible as it would have 
necessitated a fragmented approach to community engagement and 
release logistics which would have considerably complicated and 
delayed the implementation. The Brazil deployments were also an 
opportunity to optimise methods for large-scale deployment, and 
to evaluate the public health impact of a large contiguous release 
where the intervention area is likely to encompass a greater 
proportion of people’s daily movements, compared to a cluster 
randomised trial design. The controlled ITS is appropriate for the 
pragmatic evaluation of large-scale Wolbachia deployments given 
the long and reliable time series of dengue mandatory reporting 
data from both Rio de Janeiro and Niterói that allows for a 
longitudinal assessment of dengue trends before and after the 
Wolbachia intervention. Assessment of an impact of the interven-
tion on chikungunya and Zika may be more difficult given their 
shorter time series.
Notifiable disease surveillance data can be limited by a lack of 
specificity in case definitions and inconsistent reporting practices, 
which may influence our ability to detect a true intervention 
effect on arboviral disease incidence. A subset of notified dengue 
cases are supported by laboratory diagnostic results, but these 
have several limitations: i) laboratory testing occurs infrequently 
(<15% of notified cases), particularly during outbreaks, ii) the 
cross-reactivity of IgM serology between dengue and Zika limits 
the utility of serological data since 2015, and iii) the restricted 
use of PCR in only certain patient populations limits the generalis-
ability of PCR-positivity rates to all notified cases. We therefore 
base our analyses on all notified cases (suspected and confirmed). 
Benefits of using these routinely collected data include the 
availability of a long time series, reduced costs for data collec-
tion and timely acquisition of data. The non-randomized and 
unblinded nature of the Wolbachia intervention means it is 
plausible that community awareness could alter health-care 
seeking behaviour, diagnostic or reporting practices in areas 
where Wolbachia releases have been conducted. However we 
believe it is unlikely this would be of sufficient magnitude to 
result in a biased estimation of the intervention effect, since the 
intervention is deployed throughout such a large, diverse and 
complex setting (>120km2, with population >1 million). We also 
cannot exclude the possibility of a concurrent change in socio-
demographic or ecological factors related to dengue risk, or a 
change in dengue control practices, between the intervention and 
control areas independent of the Wolbachia intervention, but given 
the strong synchrony in dengue incidence between intervention 
and control zones for over a decade prior to releases this is 
considered unlikely. 
Human mobility also presents a potential challenge to this study, 
especially during the period in which staged releases are occur-
ring and Wolbachia levels are heterogeneous, as individuals are 
likely to spend time in both Wolbachia-treated and untreated areas, 
making it difficult to determine the place of illness acquisition 
among notified cases of arboviral disease. Travel between areas 
means that the true Wolbachia exposure status of individuals 
resident in Wolbachia-treated and untreated areas becomes more 
similar, thereby diluting the observed intervention effect towards 
the null.
The introduction of Zika and chikungunya viruses brought new 
challenges to health surveillance and a greater willingness for 
better vector control in affected regions. With the re-emergence of 
yellow fever in Brazil8, there is even more potential public health 
benefit if the Wolbachia intervention successfully reduces the 
vector competence of Ae. aegypti mosquitoes in the field and 
reduces arboviral disease incidence. No specific treatment for 
dengue, chikungunya or Zika currently exists. Although a vaccine 
against dengue (Sanofi Dengvaxia®) was licensed in 2015, it 
was recently found to enhance the severity of subsequent 
dengue infection in individuals who were seronegative at the time 
of vaccination. As a result, a serology test prior to the admin-
istration of the vaccine is required to confirm previous dengue 
infection, increasing costs and decreasing feasibility in high-burden 
areas34.
Releases of Wolbachia are completed or underway in eight 
countries, with no evidence of local transmission of dengue, Zika 
or chikungunya in places where Wolbachia is established at high 
levels21. The implementation of the Wolbachia intervention is 
complex and has not been done on a large scale in very densely 
populated urban areas in the Americas before. The implementation 
of the project was preceded by careful work to engage the 
community and gain public acceptance for the intervention, 
even in the most difficult contexts of poverty and urban violence 
present in both Rio de Janeiro and Niterói. Engagement, 
entomological monitoring, and public health impact assessment 
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activities were developed in close partnership with local 
governments. If the current project is successful, this model can be 
expanded to the rest of the country and the Americas.
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This manuscript describing the protocol for an intervention trial of Wolbachia replacement in 
Aedes aegypti populations with the wMel Wolbachia strain to prevent dengue, Zika and 
chikungunya in the complicated densely populated urban environments of Rio de Janeiro and 
Niteroi, Brazil, has been revised somewhat in response to previous open reviewers. In response to 
both reviewers, the authors explain the pragmatic reasoning behind not conducting the study as a 
cluster randomized trial.  In addition to community pressure to deploy the intervention quickly 
and in wide areas as a result of the Zika outbreak, the authors indicate that the necessary 
community engagement to set up clusters was not feasible given the resources available and that 
the smaller geographic units are more susceptible to contamination.  In response to reviewer 1, 
the authors clarify the Wolbachia strain used and state that the wMel strain has persisted at high 
levels for over two years in Indonesia and as many as 8 years in northern Australia.  
 
Each city has four intervention release zones (ranging from 9 to 51 square kms and populations 
densities from 1,400-18,000 persons/square km) and a large non-release control area.  Adult 
mosquito releases took place between late 2015 and the end of 2019 and lasted for at least 16 
weeks in each release zone. Wolbachia introgression frequency monitoring is done with BG traps 
and PCR testing of a sample of the mosquitoes collected. The study design main analysis 
methodology is controlled interrupted time series which makes use of routinely collected public 
health disease surveillance data and requires that consistent historical data is available supporting 
the comparability of the intervention and control areas. The analysis compares the incidence of 
suspect and confirmed dengue cases before and after the intervention in the treatment and 
control zones. Additional details on the regression analysis have been provided.   Power estimates 
from simulations based on binomial distribution of ten year historical data suggest that the study 
has 80% to detect a 50% reduction after three years and a 60% reduction after two years.  
 
This study is important to assess the impact of Wolbachia replacement in a highly Aedes aegypti 
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transmitted disease endemic urban area in Latin America, as the other studies conducted by the 
World Mosquito Program have been done in Asia or in non-endemic Australia. Since the study is 
not randomized, including as much detail as possible in the description of the methods and the 




Additional details regarding the Wolbachia mosquito releases and trapping results would be 
of interest. Why were releases done as adult mosquito releases and not eggs as in the 
Yogyakarta Indonesia RCT trial?1 Were releases in all release zones begun simultaneously or 
staggered?  Were the BG trap adult female Aedes aegypti mosquito counts/densities 
comparable in the different zones and control area? Will the study design enable the 
assessment of the impact of Wolbachia releases on Aedes species abundance?  
 
○
Large dengue outbreaks had not occurred prior to the intervention in the study cities since 
2013. Is there available seroprevalence data for dengue and Zika in the intervention zones 
and the control area prior to the wMel intervention? Do we know if pre-intervention 
reported Zika incidence in 2016 was comparable in the intervention and control areas?  
 
○
The analysis plan is to report results two years after the completion of releases. If the 




Are the secondary endpoint analyses of severe dengue cases and fatalities intended to 
strengthen the efficacy evidence with data on confirmed diagnoses, to help address the cost 
effectiveness of the intervention, or to address a question of whether Wolbachia reduces 
the severity of the disease when transmission does occur?   
○
The protocol states that the study will continue through 2023 and analyses will be done 
each year for 5 years. Since the releases finished at the end of 2019, will an analysis of the 




The statement in the last paragraph of page 9 that we have no evidence of dengue, Zika or 
chikungunya transmission where high levels of Wolbachia have been established is 
somewhat misleading in that the authors are referring to northern Australia where Aedes 
aegypti transmitted diseases are not endemic and the force of infection is considerably 
lower than Asia and Latin America.  
 
○
The comment on page 9, next to last paragraph, with regard to the licensed CYD-TDV 
vaccine being rendered less feasible in high burden areas because of the need for pre-
vaccination screening actually better applies to low to moderate burden areas. WHO 
included in its 2018 vaccine recommendations2 that areas with dengue seroprevalence of 
80% or greater in 9 years might consider forgoing pre-vaccination screening. In low burden 
regions the risk of vaccinating false serologic positives increases and the cost effectiveness 
decreases. The authors may want to clarify whether they think Wolbachia replacement 
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Review: 
The authors present the study protocol for an ongoing large deployment of Wolbachia-infected 
Aedes-aegypti mosquitoes in Rio de Janeiro and Niteroi municipalities in southeastern Brazil where 
Aedes-borne diseases, especially dengue, are common. The study design is a quasi-experimental 
study (QES) that allows the application of the controlled interrupted time series analysis to 
evaluate whether Wolbachia strategy is effective in this region. The manuscript is well written and 
the study, when completed, has great potential for evaluating the promising Wolbachia strategy 
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for controlling Aedes-borne diseases. However, I have some concerns about this study and the 




First of all, the authors failed to indicate the strain of Wolbachia used in this study. Different strains 
of Wolbachia have different characteristics that enable them to invade the wild type population 
and establish themselves. The wMel strain was used in Townsville, Australia1 and was claimed to 
be successful. However, with climate change and variability in temperature, some Wolbachia-
infected mosquitoes with different strains, include wMel, cannot maintain their Wolbachia status2. 
Hence, even if the intervention works, an introduction of infected patients into such a population 
will result in an outbreak and all the gains from Wolbachia strategy would have been lost as the 
majority of the mosquitoes are now uninfected3. 
  
Figure 1 in the manuscript shows the map of the treated and untreated zones. These are adjacent 
zones, especially for the treated and untreated zones. Mosquitoes movement from untreated zone 
to treated zone could prevent Wolbachia invasion4 and vice versa. Hence, and since this is a study 
that takes a few years, mosquitoes migration cannot be ruled out. Thus, the control zones 
(untreated) is not suitable anymore.
The controlled interrupted time-series method.○
The authors stated that the reason for favoring quasi-experimental design (QED) over randomized 
controlled trial (RCT) was due to time constraints as stakeholders and funders wanted to scale-up 
the deployment of Wolbachia to accelerate the control of the emergent Zika virus in this region. 
However, in this set-up, to carefully randomize zones as treated or not should not take much time. 
In fact, since the incidence of Aedes-borne virus infections is similar between treated and untreated 
zones (Figure 2), that should be a motivation for randomizing the zones. I am thinking there are 
other reasons for ditching RCT. The authors should elaborate on this. 
For the controlled interrupted analysis, the authors plan to perform first, the descriptive analysis 
of the seasonal and inter-annual trends in the Aedes-borne infection notifications. It will be great if 
the authors are more specific about the types of descriptive analysis they intend to carry out. Also, 






The title indicated controlling “arboviral disease incidence”. The authors can be more 




I think the clause in the fourth line will flow better if “Aedes-borne diseases dengue, 
chikungunya and Zika” is changed to  “Aedes-borne diseases (dengue, chikungunya and 
Zika).
1. 
Change “km2” to “km2”.2. 
Methods
Figure 2 shows the comparative incidence of dengue for the treated and untreated regions. 
What about Zika and Chikungunya that the study is trying to control too? I think this is a 
1. 
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dengue control study that has the potential to control Zika and Chikungunya in these 
regions. It will be great if the authors make it appear so. As it is, it seems to be a study 
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Katherine ANDERS, Monash University, Melbourne, Australia 
Major comments 
 
1.    The authors failed to indicate the strain of Wolbachia used in this study. Different 
strains of Wolbachia have different characteristics that enable them to invade the 
wild type population and establish themselves. The wMel strain was used in 
Townsville, Australia and was claimed to be successful. However, with climate change 
and variability in temperature, some Wolbachia-infected mosquitoes with different 
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strains, include wMel, cannot maintain their Wolbachia status. Hence, even if the 
intervention works, an introduction of infected patients into such a population will 
result in an outbreak and all the gains from Wolbachia strategy would have been lost 
as the majority of the mosquitoes are now uninfected.  
Thank you for drawing our attention to this oversight. We have now indicated the strain 
used (wMel) in the abstract, the sixth paragraph of the introduction, the ‘Wolbachia release 
and monitoring’ subheading of the Methods, and the first paragraph of the discussion. 
While it is true that other Wolbachia strains have been shown to have higher thermostability 
than wMel in the mosquito larval life stages, the effect of heatwaves on wMel Wolbachia 
prevalence in Wolbachia-treated areas of northern Australia has been shown to be transient 
(Ross et al, PLoS NTD 2020). Long-term monitoring of WMP’s release sites in northern 
Australia and Yogyakarta, Indonesia, has demonstrated sustained high levels of Wolbachia 
2 – 8 years post-release. Entomological monitoring of Wolbachia prevalence in local Ae. 
aegypti populations in the Rio and Niteroi release areas is currently ongoing, and so will 
provide empirical evidence of the level to which wMel introgression is sustained over time. 
 
2.    Figure 1 in the manuscript shows the map of the treated and untreated zones. 
These are adjacent zones, especially for the treated and untreated zones. Mosquitoes 
movement from untreated zone to treated zone could prevent Wolbachia invasion4 
and vice versa. Hence, and since this is a study that takes a few years, mosquitoes 
migration cannot be ruled out. Thus, the control zones (untreated) is not suitable 
anymore. 
It is true that Wolbachia could theoretically spread from the deployment areas into the 
untreated control zones, however the rate of spread is known to be relatively slow 
especially in dengue urban environments like these (100-200m per year; Schmidt et al PLoS 
Biol 2017). Given the size of the control zone (117km2 in Rio de Janeiro, and 51km2 in 
Niteroi), it is highly unlikely that Wolbachia establishment will occur in any meaningful way 
beyond the border area of the control zones within the 5 year timeframe of this study.  
 
3.    The authors stated that the reason for favoring quasi-experimental design (QED) 
over randomized controlled trial (RCT) was due to time constraints as stakeholders 
and funders wanted to scale-up the deployment of Wolbachia to accelerate the control 
of the emergent Zika virus in this region. However, in this set-up, to carefully 
randomize zones as treated or not should not take much time. In fact, since the 
incidence of Aedes-borne virus infections is similar between treated and untreated 
zones (Figure 2), that should be a motivation for randomizing the zones. I am thinking 
there are other reasons for ditching RCT. The authors should elaborate on this. 
The randomization itself would not necessarily take a lot of time, although there would be 
additional work required to define an adequate number of spatial units for randomization 
(ideally based on a power calculation), and define those spatial units with ‘hard’ borders 
which minimise contamination between treated and untreated areas. The time delays come 
from the added complexity of conducting the intensive community and stakeholder 
engagement that is needed prior to releases, and conducting the deployments themselves, 
across a fragmented set of release areas interspersed with untreated control areas, 
compared to conducting these engagement and deployment activities in a contiguous 
release area. Please see our response to Reviewer 1’s comments #1, #7 and #11 for further 
discussion of the reasons for non-randomisation, and for the references to where we have 
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improved discussion of this point in the manuscript text. 
 
4.    For the controlled interrupted analysis, the authors plan to perform first, the 
descriptive analysis of the seasonal and inter-annual trends in the Aedes-borne 
infection notifications. It will be great if the authors are more specific about the types 
of descriptive analysis they intend to carry out. Also, a schematic of the expected 
trend in the notifications accounting for confounders will greatly help the protocol 
The descriptive analysis will simply describe the seasonal and interannual trends, as stated. 
I.e. the calendar months in which dengue incidence has historically been highest and lowest 
in the two cities, and the range in annual case counts and per capita incidence. We don’t see 
that this level of detail is of value to the reader here. We don’t understand the reviewer’s 
suggestion about a schematic of expected trend in notifications. We show in figure 2 the 
historical trends in dengue incidence in the intervention area and untreated control area for 
each city; the lines for intervention and control area can be expected to diverge if Wolbachia 
successfully interrupts dengue transmission. 
Minor comments 
 
5.    The title indicated controlling “arboviral disease incidence”. The authors can be 
more specific if they change that to either “Aedes-borne disease incidence” or 
something more specific. 
We have changed the wording in the title to ‘Aedes-borne disease’ as suggested. 
 
6.    I think the clause in the fourth line [of the abstract] will flow better if “Aedes-
borne diseases dengue, chikungunya and Zika” is changed to  “Aedes-borne diseases 
(dengue, chikungunya and Zika). 
We have kept the original wording here, because strictly these three are not the only 
Aedes¬-borne diseases, but they are the Aedes-borne diseases were are considering in this 
protocol. 
 
7.    Change “km2” to “km2” 
This change has been made. 
 
8.    Figure 2 shows the comparative incidence of dengue for the treated and untreated 
regions. What about Zika and Chikungunya that the study is trying to control too? I 
think this is a dengue control study that has the potential to control Zika and 
Chikungunya in these regions. It will be great if the authors make it appear so. As it is, 
it seems to be a study deliberately targeting all the three Aedes-borne diseases 
See response to comment #13, Reviewer 1. 
Historical chikungunya data for the intervention areas and control areas is now included as 
Figure 3.  
Competing Interests: None
Reviewer Report 07 November 2019
https://doi.org/10.5256/f1000research.21787.r51960
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Liz Turner   
Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA 
This very well written manuscript describes the protocol for a quasi-experimental study using 
controlled interrupted time series. The study is currently being conducted in Brazil. The selected 
design is an innovative use of the controlled interrupted time series which can leverage routinely 
collected surveillance data to seek to address causal questions of interest. Moreover, the 
intervention being evaluated, namely the deployment of Wolbachia mosquitoes with the goal to 
reduce arboviral disease incidence, is innovative and shows great promise. 
  
I have two main comments:
A desire to see more justification for why randomization was not possible. The difficulties of 
randomization in this setting are mostly described but, as you’ll see from my more detailed 
comments below, it’s not absolutely convincing that randomization would not have been 
possible here, even within the interrupted time series design. 
 
○
Because the measurement of incidence of the arbobviruses of interest is mostly through 
surveillance data and it may be difficult to blind communities to the use of Wolbachia, how 
can it be determined that in the treatment zones post-Wolbachia release any smaller 
incidence is not just related to the fact that there is lower reporting as community members 
expect the incidence of those viruses to go down? I have a big concern about the possibility 
of differential assessment of outcomes in treated and control zones. Can the authors 
elaborate on this in relevant places in the text?
○
Here I offer some more minor points that may help with clarity for the reader: 
  
Abstract
It could help the reader if when “dengue, chikungunya and Zika” are first mentioned in the 
abstract, they are also named as arboviruses i.e. to help readers not necessarily familiar 
with them to be certain that all three fall in to this class of viruses.
○
Background
Based on the title referring to arboviruses, as a reader, I was expecting the first sentence or 
so to at least mention of arbovirus. Would it be possible to do so? This could be achieved 
very easily by saying something like “The global incidence of the arbovirus dengue has 
increased dramatically in recent decades.” 
 
○
In the 4th paragraph referring to yellow fever, please clarify if is an arbovirus. 
 
○
The last sentence of the 6th paragraph: “Laboratory data indicate a similar reduction in the 
competence of Wolbachia-carrying Ae. aegypti for transmitting other viruses including Zika, 




In the 9th paragraph, I very much appreciate the rationale that there was demand for scale-○
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up of implementation of the Wolbachia releases. I would appreciate a little more clarity on 
why randomization was not possible since, given that not all areas of the study will receive 
the treatment during the study, the scale-up argument doesn’t seem sufficient to justify no 
randomization. I can very well imagine that there are many compelling reasons to not 
randomize, some of which are alluded to, and so it would help to be even clearer about this 
e.g. was it because of the existing partnerships and infrastructure making certain areas 
better for release than others? What else? Some of this is sort of implied in the text and it 
would be valuable to have just a few more explicit sentences regarding this. 
 
Related to my previous comments on arboviruses, in the 10th paragraph where it is stated: 
“Here we describe a protocol for evaluating the effect of large scale non-randomized 
Wolbachia releases on the incidence of dengue, Zika and chikungunya in the municipalities 
of Niterói and Rio de Janeiro.”, again, it could really help the reader to edit this sentence to 
something like “…on the incidence of three arboviruses, namely dengue, Zika and 
chikungunya, in the……”. 
 
○
Also, see a later comment based on the discussion as to why yellow fever is not also 
included in the study.
○
Methods – Study design
Why do the two stated objectives only relate to dengue? It will be important to make clear in 
the manuscript as it is strange that the overall goals are related to three arboviruses but the 
objectives only related to one of them. 
 
○
Table 1: Are zones 1-3 in Niteroi and zones 1-3.2 in Rio the release areas? If so, please more 
clearly label this in the table as it is not immediately obvious to me when I look at the table 
even though I infer that it is the case. Perhaps add a sub-heading of “release areas” above 
the rows where the names of the release zones are provided.
○
Methods – Study setting and population 
Overall, the rationale appears reasonable for the use of controlled interrupted time series 
but, in reference to my comments above, please look for some opportunities to be even 
clearer about why randomization could not be used. An interrupted time series design 
could still be adopted, but one with randomization could offer even stronger evidence. 
 
○
“In Rio de Janeiro, two administrative areas adjacent to the release area have been 
designated a priori as a comparative control zone (Figure 1), based on comparable 
sociodemographic characteristics and synchronous historical dengue time series (Figure 2 
and Table 1).” I do not see any information on these SES characteristics except for 
population whereas I see the “synchronous historical dengue time series” data in Figure 2, 
which is really helpful. Can more info on SES be added to the appendix or is the data 
presented the extent of the available data? As a reader, I would want that information when 
judging the validity of the comparisons between treatment and control areas. Incidentally, 
is no historical data available on Zika and Chikungunga? If it is available, it would be really 
valuable to see that compared between treated and control. I see in the last paragraph of 
pg 6 that some such data is available so why not include it in the current manuscript?
○
Controlled interrupted time series
It is stated: “Zone-level ITS analyses will be performed 12 months after completion of 
releases in each zone, and each 12 months thereafter, with release zones considered 
‘treated’ for the purpose of this analysis based on completion of releases, regardless of the 
○
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long-term Wolbachia monitoring results.” What does “performed 12 months after 
completion”? Is it literally about the timing of running the analyses, even though data from 
each month will be used? The reason I ask for clarification is that on first read I thought that 
this meant there was a switch to only using data at 12 months after completion of the 
releases. Also, what is the time frame for control areas where there is no release? Please be 
more specific. 
 
“Aggregate release area level analyses will be performed for each municipality 12 months 
after completion of releases in the last zone and each 12 months thereafter.” What are 
municipalities? Please define this term when it is first introduced as I don’t see this term 
defined elsewhere. Is it city i.e. Rio and Niteroi? If so, why not just use the same term 
throughout i.e. municipality or city, and only choose one of those terms? 
 
○
Regarding analyses, I recognize that there may not be space but it would be beneficial to 
provide some more details including: 
 
Model diagnostics to be used e.g. what happens if there is even more dispersion than 
can be accommodated than the proposed negative binomial models? 
 
○
How will contrasts be made between the treated and control communities? As far as I 
can tell, this is not specified, though perhaps I’m missing it? Please specific which 
parameters will be used to estimate the “treatment” effect. 
 
○
How will the fact that the control zones are not randomized be accounted for in 
modelling i.e. although the set of control zones were selected to be comparable on 
average to those treated based on historical dengue incidence and SES, what about 
other factors that may be different between the treated and control zones? 
 
○
Will there be a “fake” interruption in the series for the control areas? It doesn’t seem 
necessary and may be problematic but would be valuable to describe explicitly what 




The discussion starts with a sentence on dengue, zika and yellow fever. Why is yellow fever 
not included in the outcome measures for the proposed study?
○
Overall, this is a fascinating study and a great use of an interrupted time series.
 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Not applicable
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Reviewer Expertise: Statistical methods in global health research including elimination science and 
impact evaluation with a focus on malaria and febrile illnesses
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 01 Jun 2020
Katherine ANDERS, Monash University, Melbourne, Australia 
Main comments 
 
1.    I have a desire to see more justification for why randomisation was not possible. 
The difficulties of randomisation in this setting are mostly described but, as you’ll see 
from my more detailed comments below, it’s not absolutely convincing that 
randomisation would not have been possible here, even within the interrupted time 
series design. 
We agree with the reviewer that randomisation could be combined with ITS, and in principle 
this could be a stronger design. However randomisation of the deployment (either by 
random allocation of parallel treated and untreated areas, or by randomising the sequence 
of staged deployments) would have necessitated the study site being divided up into a large 
number of spatial units for randomisation. Logistically, this would have made the 
community engagement and deployment activities infeasible within the funding and time 
constraints of the project, and in the context of the large and complex urban setting. 
Intensive stakeholder and community engagement, and deployment planning, could only 
have commenced after the randomisation process had occurred and the intervention areas 
were determined. Field activities would then have had to be conducted in a spatially 
fragmented way, complicating the stakeholder and community engagement and the 
deployment logistics and inevitably lengthening time frames. Smaller non-contiguous 
release areas interspersed with untreated areas would also have greatly increased the 
potential for contamination between treatment arms from both mosquito movement and 
human movement, thereby diluting the observable intervention effect. Please see our 
responses to comments #7 and #11 below, and Reviewer 2 comment #3. 
 
2.    Because the measurement of incidence of the arboviruses of interest is mostly 
through surveillance data and it may be difficult to blind communities to the use of 
Wolbachia, how can it be determined that in the treatment zones post-Wolbachia 
release any smaller incidence is not just related to the fact that there is lower 
reporting as community members expect the incidence of those viruses to go down? I 
have a big concern about the possibility of differential assessment of outcomes in 
treated and control zones. Can the authors elaborate on this in relevant places in the 
text? 
It is plausible that community awareness could alter health-care seeking behaviour, or 
diagnostic / reporting practices, in areas where Wolbachia releases have been conducted. 
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However we find it unlikely that this could lead to a large and sustained difference in 
dengue case notifications across two cities as large and complex as these, where the total 
intervention area exceeds 120km2 and 1 million inhabitants. Dengue (and chikungunya and 
Zika) is a notifiable disease, so there remains a requirement for health care providers to 
report any suspected cases meeting the standard case definition. We have included a 
discussion of this as potential limitation, in the fourth paragraph of the discussion. From the 
beginning of the project's engagement with communities, all messaging has reinforced the 




3.    It could help the reader if when ‘dengue, chikungunya and Zika’ are first 
mentioned in the abstract, they are also named as arboviruses i.e. to help readers not 
necessarily familiar with them to be certain that all three fall in to this class of viruses. 
Since the three arboviruses of interest are specifically those vectored by Aedes mosquitoes, 
for greater clarity we have replaced ‘arboviruses’ with ‘Aedes-borne viruses’ in most 
instances throughout the abstract and article text, including in the manuscript title. 
Elsewhere we have replaced ‘arboviral disease’ with the more intuitive term ‘mosquito-
borne disease’. In the last sentence of paragraph one, it is made clear that the term 
‘arbovirus’ encompasses dengue, chikungunya, Zika, yellow fever and Mayaro viruses, and 
that these are specifically Aedes-borne arboviruses. 
 
4.    Based on the title referring to arboviruses, as a reader I was expecting the first 
sentence or so to at least mention arbovirus. Would it be possible to do so? This could 
be achieved very easily by saying something like “The global incidence of the 
arbovirus dengue has increased dramatically in recent decades”. 
As above, the manuscript title has been adjusted to replace ‘arboviral disease’ with ‘Aedes-
borne disease’ to improve clarity for the reader. The first sentence introduces dengue (the 
disease) as a global public health challenge, and the last sentence of that paragraph defines 
dengue, chikungunya and Zika (and yellow fever and Mayaro) as Aedes-borne diseases (and 
arboviruses). A definition of arbovirus as meaning a mosquito-borne virus has also been 
added to this sentence. 
 
5.    In the fourth paragraph referring to yellow fever, please clarify if it is an 
arbovirus. 
Yellow fever has been defined as an Aedes-borne arboviruses in the last sentence of the 
first paragraph of the introduction. 
 
6.    The last sentence of the sixth paragraph: “Laboratory data indicate a similar 
reduction in the competence of Wolbachia-carrying Ae. aegypti for transmitting other 
viruses include ZIka, chikungunya, yellow fever and Mayaro”. If all listed are 
arboviruses, please edit ‘viruses’ to ‘arboviruses’. 
The text has been corrected as suggested. 
 
7.    In the ninth paragraph, I very much appreciate the rationale that there was 
demand for scale-up of implementation of the Wolbachia releases. I would appreciate 
a little more clarity on why randomization was not possible since, given that not all 
 
Page 23 of 27
F1000Research 2020, 8:1328 Last updated: 24 DEC 2020
areas of the study will receive the treatment during the study, the scale-up argument 
doesn’t seem sufficient to justify no randomization. I can very well imagine that there 
are many compelling reasons to not randomize, some of which are alluded to, and so 
it would help to be even clearer about this e.g. was it because of the existing 
partnerships and infrastructure making certain areas better for release than others? 
What else? Some of this is sort of implied in the text and it would be valuable to have 
just a few more explicit sentences regarding this. 
Please see our response to Major comment #1 above. We have added text to the end of the 
ninth paragraph of the introduction, expanding on this justification for not randomising, as 
suggested. 
 
8.    Related to my previous comments on arboviruses, in the tenth paragraph…again 
it could really help the reader to edit this sentence to something like “…three 
arboviruses, namely dengue, Zika and chikungunya…” 
Consistent with our response to comment # above, we have adjusted the wording in the 
paragraph to refer to dengue, Zika and chikungunya as ‘Aedes-borne diseases’ or 
‘mosquito-borne diseases’. 
 
9.    Why do the two stated objectives only relate to dengue? It will be important to 
make clear in the manuscript as it is strange that the overall goals are related to three 
arboviruses but the objectives only related to one of them. 
Thank you for pointing out this inconsistency, we have corrected the wording of the aims 
and first objective to be inclusive of dengue, chikungunya and Zika (as the Aedes-borne 
diseases of interest). The second objective still relates only to dengue, as the outbreak 
indicators used routinely for public health purposes in Rio and Niteroi apply only to dengue 
outbreak monitoring. As explained under ‘Controlled interrupted time series analysis’ (3rd 
and 4th paragraphs, page 11), the primary endpoint for the ITS analysis will be dengue for 
which there is the longest historical case time series, with chikungunya and Zika analysed as 
secondary endpoints in the ITS. 
 
10.     Table 1: Are zones 1-3 in Niteroi and zones 1-3.2 in Rio the release areas? If so, 
please more clearly label this in the table as it is not immediately obvious to me. 
Perhaps add a sub-heading of “release areas” above the rows where the names of the 
release zones are provided. 
Thank you for this suggestion, we have improved the labelling of the areas in Table 1 to 
make clearer which are the release zones and non-release areas. Please note that we have 
also updated this table and Figure 2 to reflect an additional release zone in Niteroi (and the 
consequent reduced size of the control area). 
 
11.    Overall the rationale appears reasonable for the use of controlled interrupted 
time series but, in reference to my comments above, please look for some 
opportunities to be even clearer about why randomisation could not be used. An 
interrupted time series design could still be adopted, but one with randomisation 
could offer even stronger evidence. 
Please see our responses to comments #1 and #7 above. Additional discussion of the 
justification for not randomising, and the potential benefits from the pragmatic evaluation 
of a large-scale contiguous release, has been added to the third paragraph of the discussion 
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section on page 12. 
 
12.    “In Rio de Janeiro, two administrative areas adjacent to the release area have 
been designated a priori as a comparative control zone (Figure 1), based on 
comparable sociodemographic characteristics and synchronous historical dengue 
time series (Figure 2 and Table 1).” I do not see any information on these SES 
characteristics except for population whereas I see the “synchronous historical 
dengue time series” data in Figure 2, which is really helpful. Can more info on SES be 
added to the appendix or is the data presented the extent of the available data? As a 
reader, I would want that information when judging the validity of the comparisons 
between treatment and control areas.  
Unfortunately socio-economic data are not available aggregate to the release zones. We 
have now corrected this text to clarify that the comparability of the untreated control areas 
is demonstrated by the synchronous historical dengue time series. 
 
13.    Incidentally, is no historical data available on Zika and Chikungunga? If it is 
available, it would be really valuable to see that compared between treated and 
control. I see in the last paragraph of pg 6 that some such data is available so why not 
include it in the current manuscript? 
Historical chikungunya data for the intervention areas and control areas is now included as 
Figure 3. 
 
14.    It is stated: “Zone-level ITS analyses will be performed 12 months after 
completion of releases in each zone, and each 12 months thereafter, with release 
zones considered ‘treated’ for the purpose of this analysis based on completion of 
releases, regardless of the long-term Wolbachia monitoring results.” What does 
“performed 12 months after completion”? Is it literally about the timing of running 
the analyses, even though data from each month will be used? The reason I ask for 
clarification is that on first read I thought that this meant there was a switch to only 
using data at 12 months after completion of the releases. Also, what is the time frame 
for control areas where there is no release? Please be more specific. 
Yes, this is about the timing of running the analyses, ie. the intervention effect will be 
estimate for each zone when 12 months of post-release observations have accumulated in 
that zone, and repeated each 12 months thereafter (for five years) on cumulative post-
release observations. And the same for the city-level analyses. The text at the end of the first 
paragraph under the heading ‘Controlled interrupted time series analysis’ has been edited 
to clarify this. There is no separate analysis for control areas, these are included in the 
regression model as the comparator for each individual release zone, and for the city-level 
analysis. This has been clarified in the text. 
 
15.    “Aggregate release area level analyses will be performed for each municipality 12 
months after completion of releases in the last zone and each 12 months thereafter.” 
What are municipalities? Please define this term when it is first introduced as I don’t 
see this term defined elsewhere. Is it city i.e. Rio and Niteroi? If so, why not just use 
the same term throughout i.e. municipality or city, and only choose one of those 
terms? 
We recognise this inconsistency may have been confusing, and have changed throughout to 
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use ‘city/cities’ in place of ‘municipality/municipalities’. 
 
16.    Model diagnostics to be used e.g. what happens if there is even more dispersion 
than can be accommodated than the proposed negative binomial models? 
Of the common count models, negative binomial models have the most flexible approach 
for handling overdispersion in count data by assuming that the variance is a quadratic 
function of the mean. Common causes of overdispersion can range from an excess of zero 
counts, unexplained heterogeneity, and/or temporal autocorrelation. The models as 
proposed will be using flexible cubic splines to explain secular and temporal trends, 
hopefully leaving very little remaining unexplained heterogeneity. To account for any 
lingering heteroskedasticity or temporal autocorrelation, heteroskedasticity-robust 
estimation will be used for estimating variance. This has now been made explicit in the 
description of the Controlled interrupted time series methods. If an excess of zero counts is 
apparent, the proposed negative binomial model will be nested within a zero-inflated 
negative binomial model of the same structure. A likelihood ratio test can be performed to 
test model fit. This is also now described in the methods. 
 
17.    How will contrasts be made between the treated and control communities? As far 
as I can tell, this is not specified, though perhaps I’m missing it? Please specific which 
parameters will be used to estimate the “treatment” effect 
The regression model will use monthly dengue case time series data for the treated area 
(either an individual release zone or aggregate city-level release area, as specified in the 
text) and the control area (one control area per city). The treatment effect will be estimated 
from the interaction between a binary ‘area’ variable (treated vs control) and a binary 
‘period’ variable (post-Wolbachia vs pre-Wolbachia). This allow explicitly for a level change in 
the outcome (dengue case incidence) in both intervention and control arms in the post-
intervention period, for example in a scenario where other secular events coincident with 
the Wolbachia deployments may have influenced dengue incidence in both intervention and 
control areas independent of Wolbachia. The text under ‘Controlled interrupted time series’ 
has been revised to clarify this. 
 
18.    How will the fact that the control zones are not randomized be accounted for in 
modelling i.e. although the set of control zones were selected to be comparable on 
average to those treated based on historical dengue incidence and SES, what about 
other factors that may be different between the treated and control zones? 
Quasi-experimental designs, such as the proposed ITS analysis, aim to address the validity 
concerns associated with non-randomization in several ways. By using a region's historic 
data to inform the counterfactual outcome, the ITS analysis aims to minimize threats to 
internal validity. Second, by adding control regions and performing a controlled ITS, we 
better account for seasonal and secular influences during both the pre- and post-
intervention periods. While it is true that there may be other factors associated with dengue 
risk that differ between treated and control zones in a non-randomised design, we make 
the implicit assumption in the controlled ITS that these differences are consistent 
throughout both the pre- and post-intervention period. Any divergence in the post-
intervention period from the synchrony in dengue time series observed between 
intervention and control zones in the pre-intervention period is therefore assumed to 
represent an intervention effect. However we cannot exclude the possibility of a concurrent 
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change in socio-demographic or ecological factors related to dengue risk, or a concurrent 
change in dengue control practices, between the intervention and control areas independe 
of the Wolbachia intervention. We have expanded on this limitation in the discussion. 
 
19.    Will there be a “fake” interruption in the series for the control areas? It doesn’t 
seem necessary and may be problematic but would be valuable to describe explicitly 
what will be done in the time series modelling for the control zones. 
The inclusion of the control area time series in the regression model and estimation of the 
intervention effect from an interaction between ‘area’ and ‘period’ effectively does allow for 
a ‘fake’ interruption in the series for the control area, as it allows for a step change in the 
control area as well as the treated area, post-intervention. The interaction parameter from 
which the intervention effect is estimated indicates whether there was any change in 
dengue incidence following the Wolbachia intervention in areas where Wolbachia releases 
occurred, over and above any change in dengue incidence that was observed in the 
untreated control area. 
 
20.    The discussion starts with a sentence on dengue, zika and yellow fever. Why is 
yellow fever not included in the outcome measures for the proposed study? 
Yellow fever is not included as an endpoint for the study because there is not a history of 
urban yellow fever in the cities of Rio and Niteroi. The recent outbreak in Rio de Janeiro 
state that is mentioned early in the discussion included some urban cases, but in other 
parts of the state. We have removed that sentence from the first paragraph of the 
discussion, to avoid confusion.  
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